Site‐Selective Tyrosine Reaction for Antibody‐Cell Conjugation and Targeted Immunotherapy
Hongfei Chen,Hong‐Chai Fabio Wong,Jiaming Qiu,Biquan Li,Dingdong Yuan,Hao Kong,Yishu Bao,Yu Zhang,Zhiyi Xu,Ying‐Lung Steve Tse,Jiang Xia
DOI: https://doi.org/10.1002/advs.202305012
IF: 15.1
2023-12-05
Advanced Science
Abstract:Achieving site‐selective reactions at a single tyrosine residue, while leaving others untouched within the same protein, can be challenging. Here, a one‐pot chemoenzymatic reaction is developed to install fluorescent or bioorthogonal groups at Y296 on the Fc domain of IgGs or a Y‐tag of an engineered nanobody, and applied it to construct monofunctionalized antibody‐drug conjugates and antibody/nanobody‐conjugated effector cells. Targeted immunotherapies capitalize on the exceptional binding capabilities of antibodies to stimulate a host response that effectuates long‐lived tumor destruction. One example is the conjugation of immunoglobulins (IgGs) to immune effector cells, which equips the cells with the ability to recognize and accurately kill malignant cells through a process called antibody‐dependent cellular cytotoxicity (ADCC). In this study, a chemoenzymatic reaction is developed that specifically functionalizes a single tyrosine (Tyr, Y) residue, Y296, in the Fc domain of therapeutic IgGs. A one‐pot reaction that combines the tyrosinase‐catalyzed oxidation of tyrosine to o‐quinone with a subsequent [3+2] photoaddition with vinyl ether is employed. This reaction installs fluorescent molecules or bioorthogonal groups at Y296 of IgGs or the C‐terminal Y‐tag of an engineered nanobody. The Tyr‐specific reaction is utilized in constructing monofunctionalized antibody‐drug conjugates (ADCs) and antibody/nanobody‐conjugated effector cells, such as natural killer cells or macrophages. These results demonstrate the potential of site‐selective antibody reactions for enhancing targeted cancer immunotherapy.
materials science, multidisciplinary,nanoscience & nanotechnology,chemistry